Parkinson&apos
Conditions
Interventions
This is a randomized pilot study with three comparative groups (two intervention conditions and one educational control group). All participants will receive an educational booklet about the sensation
s disease. The control group will not receive additional treatment. The two intervention groups (global ALM and localized ALM) will participate in supervised sessions twice a week, on alternate days,
s disease, covering the body as a whole, regardless of the location of the pain reported by the patient, as described in the literature and based on the clinical experience of the researchers involved
b) hip and spine
c) lower limbs, ankles and feet. In total, 15 patients will undergo the ALML protocol, which may be distributed asymmetrically among these three subgroups, depending on the pain reported by each patie
s disease and musculoskeletal pain.
Sponsors
Universidade Federal de Minas Gerais
Associação dos Parkinsonianos de Minas Gerais
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Individuals with a clinical diagnosis of Parkinson's disease according to the United Kingdom Parkinson's Disease Society Brain Bank criteria; on stable antiparkinsonian medication and with persistent nonspecific musculoskeletal pain for more than three months; participants of both sexes; over 18 years of age; preserved cognitive function.
Exclusion criteria
Exclusion criteria: Individuals diagnosed with other neurological or psychiatric diseases that compromise their participation in assessments or interventions will be excluded from the study; those who have undergone therapies that influence pain other than through exercise (such as electrotherapy, TENS, acupuncture, transcutaneous brain stimulation) or medication in the last three months; individuals with recent trauma or surgery associated with chronic musculoskeletal pain; those with pressure sores or wounds that prevent certain positions; those diagnosed with cancer or fracture in the last three months; those with pain of infectious or inflammatory origin; those with nerve root compression; those with a score of less than 2 points on the numerical pain scale in the last seven days, as these are considered very minor pains for intervention purposes; and those with visual and/or auditory impairments that hinder participation and inability to move independently will also be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study is expected to be feasible, verified by the recruitment rate (number of participants included in the study), the retention rate (number of participants who completed the intervention), and the success of the implementation within the proposed environment.;The study is expected to be acceptable, verified by the acceptance rate (the proportion of eligible participants who consented to participate), protocol engagement (the proportion of completed sessions), participants' experience with implementation (the rate of agreeableness and satisfaction), and the overall satisfaction rating.;The study is expected to be adequate, verified by the identification of adverse events that are measured by the dropout rate due to problems related to the intervention, by the patient's perception of fit, and by the compatibility of the intervention in pain management.;The study is expected to adhere to the established protocol or the planned adaptations, verified through a description of the consistency of its application and any modifications made.;The study is expected to present the reality of the intervention implementation costs measured from a societal perspective over a six-month time horizon. The costs of implementing the intervention will be comprised of intervention costs, healthcare costs, patient and family costs, and costs associated with lost patient and family productivity. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected that self-myofascial release interventions will decrease pain intensity, as measured by the numerical pain scale. A two-point decrease on the pain scale is already considered a significant improvement in pain.;It is expected that self-myofascial release interventions will decrease the presence of kinesiophobia, as measured by the Tampa Scale for Kinesiophobia. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will decrease pain catastrophizing, as measured by the Pain Catastrophic Thinking Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve overall health performance, as measured by the Global Effect Perception Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will decrease fatigue, as verified by the Fatigue Severity Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will decrease symptoms of anxiety and depression, as verified by the Beck Inventory. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve trunk mobility, as verified by the Trunk Mobility Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve the level of activities in daily living, as verified by the Activities of Daily Living Questionnaire. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve patient-specific function, as verified by the Patient-Specific Functional Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve the symptom-sp | — |
Countries
BR
Contacts
Public ContactTamires Ribeiro
Universidade Federal de Minas Gerais
Outcome results
None listed